 |
(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine |
|---|---|
| Trade Name | |
| Orphan Indication | Tuberculosis |
| USA Market Approval | USA |
| USA Designation Date | 2007-07-05 00:00:00 |
| Sponsor | Global Alliance for TB Drug Development;40 Wall Street, 24th Floor;New York, New York, 10005 |
